| | | |
每股
|
| |
total
|
| ||||||
|
公開發行價格
|
| | | $ | 62.00 | | | | | $ | 419,999,966 | | |
|
承保折扣和佣金 (1)
|
| | | $ | 3.72 | | | | | $ | 25,199,998 | | |
|
支出前收益將捐給Apogee Therapeutics, Inc.
|
| | | $ | 58.28 | | | | | $ | 394,799,968 | | |
| 傑富瑞 | | |
美銀證券
|
| |
高盛公司有限責任公司
|
| |
TD Cowen
|
| | Stifel | |
| 目錄 | | | |||||
|
招股説明書摘要
|
| | | | 1 | | |
|
風險因素
|
| | | | 9 | | |
|
關於前瞻性陳述的特別説明
|
| | | | 11 | | |
|
行業和市場數據
|
| | | | 13 | | |
|
所得款項的使用
|
| | | | 14 | | |
|
股息政策
|
| | | | 15 | | |
| 大寫 | | | | | 16 | | |
| 稀釋 | | | | | 17 | | |
|
主要股東
|
| | | | 18 | | |
|
資本存量描述
|
| | | | 21 | | |
|
有資格在未來出售的股票
|
| | | | 26 | | |
|
美國聯邦所得税對非美國的重大影響持有者
|
| | | | 28 | | |
| 承保 | | | | | 32 | | |
|
法律事務
|
| | | | 40 | | |
| 專家 | | | | | 40 | | |
|
在哪裏可以找到更多信息
|
| | | | 40 | | |
|
以引用方式納入
|
| | | | 41 | | |
| | |
2022 年 2 月 4 日
(盜夢空間)到 2022 年 12 月 31 日 |
| |
年
已結束 2023 年 12 月 |
| ||||||
| | |
(以千計,股票和
除外)
每股數據) |
| |||||||||
合併運營報表和綜合虧損數據: | | | | | | | | | | | | | |
運營費用: | | | | | | | | | | | | | |
研究和開發 (1)
|
| | | $ | 27,786 | | | | | $ | 68,424 | | |
一般和行政 (2)
|
| | | | 2,941 | | | | | | 24,579 | | |
運營費用總額
|
| | | | 30,727 | | | | | | 93,003 | | |
運營損失
|
| | | | (30,727) | | | | | | (93,003) | | |
其他收入(支出),淨額: | | | | | | | | | | | | | |
利息收入
|
| | | | 92 | | | | | | 9,018 | | |
其他融資費用
|
| | | | (9,150) | | | | | | — | | |
其他收入(支出)總額,淨額
|
| | | | (9,058) | | | | | | 9,018 | | |
淨虧損和綜合虧損
|
| | | $ | (39,785) | | | | | $ | (83,985) | | |
每股淨虧損,基本和攤薄後 (3)
|
| | | $ | (16.16) | | | | | $ | (3.36) | | |
已發行普通股、基本股和攤薄後加權平均值
|
| | | | 2,462,236 | | | | | | 25,005,774 | | |
|
| | |
截至 2023 年 12 月 31 日
|
| |||||||||
| | |
實際
|
| |
PRO FORMA (1)
|
| ||||||
| | |
(以千計)
|
| |||||||||
合併資產負債表數據: | | | | | | | | | | | | | |
現金、現金等價物和有價證券
|
| | | $ | 395,459 | | | | | $ | 786,737 | | |
營運資金 (2)
|
| | | | 377,851 | | | | | | 769,129 | | |
總資產
|
| | | | 401,404 | | | | | | 792,682 | | |
負債總額
|
| | | | 21,491 | | | | | | 21,491 | | |
累計赤字
|
| | | | (123,770) | | | | | | (123,770) | | |
股東權益總額
|
| | | | 379,913 | | | | | | 771,191 | | |
| | |
截至 2023 年 12 月 31 日
|
| |||||||||
| | |
實際
|
| |
PRO FORMA
|
| ||||||
| | |
(以千計,股票和每股數據除外)
|
| |||||||||
現金、現金等價物和有價證券
|
| | | $ | 395,459 | | | | | $ | 786,737 | | |
股東權益(赤字): | | | | | | | | | | | | | |
優先股,面值0.00001美元:已授權 10,000,000 美元,否
實際已發行和流通股份;10,000,000 股 已授權,未發行和流通股票,預期 |
| | | | — | | | | | | — | | |
普通股,面值0.00001美元:4億股
已授權,已發行50,655,671股,48,338,769股 實際已流通;已獲授權4億股股票, 已發行57,429,864股和55,112,962股 出類拔萃; |
| | | | — | | | | | | 1 | | |
額外的實收資本
|
| | | | 503,354 | | | | | | 894,631 | | |
累計其他綜合收益
|
| | | | 329 | | | | | | 329 | | |
累計赤字
|
| | | | (123,770) | | | | | | (123,770) | | |
股東權益總額
|
| | | | 379,913 | | | | | | 771,191 | | |
資本總額
|
| | | $ | 379,913 | | | | | $ | 771,191 | | |
|
|
每股公開發行價格
|
| | | | | | | | | $ | 62.00 | | |
|
截至2023年12月31日的每股淨有形賬面價值(赤字)
|
| | | $ | 7.50 | | | | | | | | |
|
歸因於本次發行的每股淨有形賬面價值增加
|
| | | | 5.93 | | | | | | | | |
|
預計本次發行後每股淨有形賬面價值
|
| | | | | | | | | | 13.43 | | |
|
在本次發行中向新投資者攤薄每股
|
| | | | | | | | | $ | 48.57 | | |
| | |
在發售之前
|
| | | | | | | | | | | | | |
在發售之後
|
| | | | | | | | | | | | | ||||||||||||||||||
受益所有人的姓名
|
| |
數字
OF 股票 OF 投票 常見 庫存 擁有 |
| |
的數量
的 股份 非- 投票 常見 庫存 擁有 |
| |
總計
百分比 所有權 (1) |
| |
投票
力量 (2) |
| |
的數量
的 股份 投票 常見 庫存 擁有 |
| |
數字
OF 股票 OF 非- 投票 常見 庫存 擁有 |
| |
總計
百分比 所有權 (3) |
| |
投票
力量 (4) |
| ||||||||||||||||||||||||
大於 5% 的股東: | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
隸屬於費爾芒特基金管理有限責任公司的實體 (5)
|
| | | | 2,048,647** | | | | | | 6,743,321 | | | | | | 17.4% | | | | | | 5.8%** | | | | | | 2,048,647** | | | | | | 6,743,321 | | | | | | 15.3% | | | | | | 4.9%** | | |
與文洛克醫療保健相關的實體
Capital Partners III,L.P. (6) |
| | | | 1,750,000** | | | | | | 6,743,321 | | | | | | 16.8% | | | | | | 5.0%** | | | | | | 1,750,000** | | | | | | 6,743,321 | | | | | | 14.8% | | | | | | 4.2%** | | |
隸屬於FMR LLC(富達)的實體 (7)
|
| | | | 5,018,880 | | | | | | — | | | | | | 9.9% | | | | | | 14.3% | | | | | | 5,018,880 | | | | | | — | | | | | | 8.7% | | | | | | 12.0% | | |
惠靈頓生物醫學創新大師(開曼)II,L.P.(8)
|
| | | | 2,527,901 | | | | | | — | | | | | | 5.0% | | | | | | 7.2% | | | | | | 2,527,901 | | | | | | — | | | | | | 4.4% | | | | | | 6.0% | | |
隸屬於深軌資本的實體,
唱片 (9) |
| | | | 2,323,456 | | | | | | — | | | | | | 4.6% | | | | | | 6.6% | | | | | | 2,323,456 | | | | | | — | | | | | | 4.0% | | | | | | 5.6% | | |
百利宮 (10) | | | | | 2,259,073 | | | | | | — | | | | | | 4.5% | | | | | | 6.4% | | | | | | 2,259,073 | | | | | | — | | | | | | 3.9% | | | | | | 5.4% | | |
與 RTW Investments, LP 關聯的實體 (11)
|
| | | | 2,142,592 | | | | | | — | | | | | | 4.2% | | | | | | 6.1% | | | | | | 2,142,592 | | | | | | — | | | | | | 3.7% | | | | | | 5.1% | | |
與 RA Capital 關聯的實體 (12)
|
| | | | 1,977,901 | | | | | | — | | | | | | 3.9% | | | | | | 5.6% | | | | | | 1,977,901 | | | | | | — | | | | | | 3.4% | | | | | | 4.7% | | |
Perceptive Contogeny Venture Fund II,LP (13)
|
| | | | 1,977,901 | | | | | | — | | | | | | 3.9% | | | | | | 5.6% | | | | | | 1,977,901 | | | | | | — | | | | | | 3.4% | | | | | | 4.7% | | |
隸屬於AI 生物技術有限責任公司的實體 (14)
|
| | | | 1,940,364 | | | | | | — | | | | | | 3.8% | | | | | | 5.5% | | | | | | 1,940,364 | | | | | | — | | | | | | 3.4% | | | | | | 4.6% | | |
已任命的執行官和董事:
|
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
邁克爾·亨德森,醫學博士 (15)
|
| | | | 705,011 | | | | | | — | | | | | | 1.4% | | | | | | 2.0% | | | | | | 705,011 | | | | | | — | | | | | | 1.2% | | | | | | 1.7% | | |
卡爾·丹布科夫斯基,醫學博士(16)
|
| | | | 123,123 | | | | | | — | | | | | | *% | | | | | | *% | | | | | | 123,123 | | | | | | — | | | | | | *% | | | | | | *% | | |
簡·普里切特·亨德森 (17)
|
| | | | 74,948 | | | | | | — | | | | | | *% | | | | | | *% | | | | | | 74,948 | | | | | | — | | | | | | *% | | | | | | *% | | |
馬克·麥肯納 (18)
|
| | | | 11,111 | | | | | | — | | | | | | *% | | | | | | *% | | | | | | 11,111 | | | | | | — | | | | | | *% | | | | | | *% | | |
彼得·哈文 (5)
|
| | | | 2,099,813** | | | | | | 6,743,321 | | | | | | 17.5% | | | | | | 6.0%** | | | | | | 2,099,813** | | | | | | 6,743,321 | | | | | | 15.4% | | | | | | 5.0%** | | |
詹妮弗·福
|
| | | | — | | | | | | — | | | | | | *% | | | | | | *% | | | | | | — | | | | | | — | | | | | | *% | | | | | | *% | | |
安德魯·戈特斯迪納,醫學博士
|
| | | | — | | | | | | — | | | | | | *% | | | | | | *% | | | | | | — | | | | | | — | | | | | | *% | | | | | | *% | | |
小威廉(BJ)瓊斯
|
| | | | — | | | | | | — | | | | | | *% | | | | | | *% | | | | | | — | | | | | | — | | | | | | *% | | | | | | *% | | |
託馬斯·基瑟拉克 (5)
|
| | | | 2,099,813** | | | | | | 6,743,321 | | | | | | 17.5% | | | | | | 6.0%** | | | | | | 2,099,813** | | | | | | 6,743,321 | | | | | | 15.4% | | | | | | 5.0%** | | |
尼米什·沙阿 (6)
|
| | | | 1,750,000** | | | | | | 6,743,321 | | | | | | 16.8% | | | | | | 5.0%** | | | | | | 1,750,000** | | | | | | 6,743,321 | | | | | | 14.8% | | | | | | 4.2%** | | |
所有執行官和董事作為一個整體
(10 人) (19) |
| | | | 4,815,172 | | | | | | 13,486,642 | | | | | | 36.1% | | | | | | 13.7% | | | | | | 4,815,172 | | | | | | 13,486,642 | | | | | | 31.9% | | | | | | 11.5% | | |
承銷商
|
| |
股票數量
|
| |||
傑富瑞有限責任公司
|
| | | | 1,896,774 | | |
美國銀行證券有限公司
|
| | | | 1,422,581 | | |
高盛公司有限責任公司
|
| | | | 1,422,581 | | |
Cowen and Company, L
|
| | | | 1,287,096 | | |
Stifel、Nicolaus & Company,In
|
| | | | 745,161 | | |
總計
|
| | | | 6,774,193 | | |
|
| | |
每股
|
| |
total
|
| ||||||||||||||||||
| | |
沒有
選項 購買 額外 分享 |
| |
WITH
選項 購買 額外 分享 |
| |
沒有
選項 購買 額外 分享 |
| |
WITH
選項 購買 額外 分享 |
| ||||||||||||
公開發行價格
|
| | | $ | 62.00 | | | | | $ | 62.00 | | | | | $ | 419,999,966 | | | | | $ | 482,999,902 | | |
我們支付的承保折扣和佣金
|
| | | $ | 3.72 | | | | | $ | 3.72 | | | | | $ | 25,199,998 | | | | | $ | 28,979,994 | | |
扣除費用前的款項歸我們所有
|
| | | $ | 58.28 | | | | | $ | 58.28 | | | | | $ | 394,799,968 | | | | | $ | 454,019,908 | | |